Verastem (VSTM) said late Thursday that the metastatic pancreatic ductal adenocarcinoma patients treated with avutometinib or Avmapki plus defactinib in combination with standard-of-care chemotherapy achieved an overall response rate of 83% as of April 25.
Under the RAMP 205 phase 1/2 trial, the company said 60 patients were treated in one of five dose regimens with the combination of avutometinib and defactinib with gemcitabine and nab-paclitaxel in frontline metastatic PDAC.
The trial showed positive safety and efficacy results, with adverse events remaining generally consistent with the previously announced safety and tolerability profile, the company said.
Verastem said it plans to register a phase 3 front-line metastatic PDAC trial, expected to start in 2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。